摘要
目的观察口服普罗布考对老年下肢动脉硬化症患者血清炎性指标及氧化低密度脂蛋白水平的变化,探讨普罗布考对老年下肢动脉硬化症的抗氧化、抗炎症作用。方法将54例老年下肢动脉硬化症患者随机分为两组:普罗布考组33例,在常规药物(硝酸酯类、抗血小板制剂、β受体阻断剂和钙离子拮抗剂等)治疗的基础上口服普罗布考片0.5 g,2次/天,持续12周;对照组21例,常规药物治疗,不服用任何调脂药物及抗氧化剂。分别于治疗前后采血检测高敏C反应蛋白、白细胞介素1β、肿瘤坏死因子α、总胆固醇及氧化型低密度脂蛋白水平。结果普罗布考组治疗后总胆固醇、氧化型低密度脂蛋白、高敏C反应蛋白、白细胞介素1β显著下降(P<0.01),肿瘤坏死因子α无明显变化;对照组治疗后上述指标均无显著变化。治疗后两组间总胆固醇、氧化型低密度脂蛋白、高敏C反应蛋白、白细胞介素1β、肿瘤坏死因子α差异有统计学意义(P<0.05)。结论普罗布考可降低老年下肢动脉硬化症患者的胆固醇水平,并具有一定程度的抗氧化和抑制动脉粥样硬化慢性炎症过程的作用。
Aim To investigate the anti-oxidation and -inflammation function of probueol in the eldedy patients with low extremity atherosclerosis disease （LEASD） by measuring plasma cholesterol, oxidized low density lipoprotein （ox-LDL） and inflammation parameters before and after treatment. Methods 54 patients were divided into treatment group （ n=33 ） and control group （n=21 ）. Patients in the treatment group took probucol besides the routine therapy. Patients in the control group only took the routine drugs. The total treatment phase was 12 weeks. All patients did not take any lipid-lowering drugs and other anti-oxidants. Before and after the treatment, the plasma cholesterol, ox-LDL, high-sensitive C reactive protein （hs- CRP）,intedeuidn-1β （IL-1β） and tumor necrosis factor-α （TNF-α）were measured. Results After treatment, the levels of hs-CRP, IL-1β, ox-LDL and cholesterol decreased significantly （ P〈0.05） ; the differences in inflammation factors, ox-LDL and cholesterol concentration between the two groups were statistically significant （ P〈0.05 ）. Conclusions Probucnl could decrease the concentration of plasma cholesterol in the old patients with LEASD. Probucol could reduce the plasma level of ox- LDL, hs-CRP and IL-1β significantly, indicating its good effect of anti-inflammation and -oxidation.
出处
《中国动脉硬化杂志》
CAS
CSCD
2006年第4期336-338,共3页
Chinese Journal of Arteriosclerosis
基金
国家卫生部保健科研基金(2001-5-006)资助
